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peroxidase enzymes, primarily myeloperoxidase, eosinophil per 
oxidase and lactoperoxidase, may play in a wide range of human
pathologies. This has been sparked by rapid developments in our
understanding of the basic biochemistry of these enzymes, a
greater understanding of the basic chemistry and biochemistry of
the oxidants formed by these species, the development of bio 
markers that can be used damage induced by these oxidants in
vivo, and the recent identification of a number of compounds that
show promise as inhibitors of these enzymes. Such compounds
offer the possibility of modulating damage in a number of human
pathologies. This reviews recent developments in our understand 
ing of the biochemistry of myeloperoxidase, the oxidants that this
enzyme generates, and the use of inhibitors to inhibit such damage.
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Overview of the Action of Myeloperoxidase and Other
Heme Peroxidases
Activation of phagocytic leukocytes is a key process in the
immune response to invading pathogens. Activation of these
cells results in the assembly of a NADPH oxidase (NOX)-2
enzyme complex at the plasma membrane and a subsequent
‘respiratory burst’, in which O2 is reduced, at the expense of
NADPH, to superoxide radicals (O2￿−).(1) This radical undergoes
rapid spontaneous or catalysed (by superoxide dismutase) dis-
mutation to give molecular oxygen and hydrogen peroxide
(H2O2).(2) High concentrations of H2O2 can be bactericidal or
cytotoxic, but lower levels have limited effects. Although this
species can be reduced, by trace iron and copper ions, to hydroxyl
radicals (HO￿), the availability of these metal ions is usually very
limited, and hence HO￿ is unlikely to be a major oxidant produced
by activated neutrophils (reviewed in Ref. 3).
The bactericidal properties of activated leukocytes have been
attributed, at least in part, to the actions of myeloperoxidase
(MPO), a heme enzyme released by activated neutrophils, from
intracellular granules. This green enzyme is the most abundant
protein in neutrophils, accounting for up to 5% of their dry mass.(4)
It is also present in monocytes, though at lower levels. The ability
of monocytes to produce this protein decreases during maturation
into macrophages, but evidence has been presented that macro-
phage-like cells, such as those detected in atherosclerotic lesions,
have associated MPO.(5,6) The biological significance of MPO is
evident from studies on people with total or incomplete MPO
deficiency. Neutrophils from such people usually phagocytose
foreign material normally, and have a prolonged respiratory burst
that produces H2O2 and O2￿− but MPO deficiency results in a
greater risk of chronic infections.(7,8)
MPO protein has little bactericidal effect per se, but enzymatic
reaction with H2O2 and halide (Cl−, Br−, I−) or pseudohalide (SCN−)
ions generates hypohalous acids: hypochlorous acid (HOCl),
hypobromous acid (HOBr), hypoiodous acid (HOI), and hypothio-
cyanous acid (HOSCN).(9–11)  These oxidants are widely believed
to be responsible for much of the anti-bactericidal activity of
neutrophils, although other oxidants (including nitric oxide (NO￿),
peroxynitrite (ONOOH) and H2O2) and enzymatic systems (e.g.,
peptides, proteases, lysozyme) clearly also play an important role.
Although the generation of oxidants by MPO is beneficial in
terms of the immune response to invading pathogens, there is
considerable evidence that inappropriate stimulation of oxidant
formation by this enzyme (wrong place, wrong time, excessive
levels) can result in host tissue damage. Thus marked damage to
cells and other biological materials (extracellular matrix, biological
fluids) has been detected at sites of inflammation (reviewed in (10,12)).
This damage has been linked with several human pathologies,
and in at least some cases experimental and/or epidemiological
evidence is available to suggest that oxidant generation by MPO
(and/or other related heme peroxidases, such as eosinophil per-
oxidase (MPO)) is, at least partially, causal. This evidence for a
role for MPO and its oxidants in human disease has been recently
reviewed,(10,12) and will not be covered further here.
Physical Properties and Structure of Myeloperoxidase and
Other Heme Peroxidases
Mature MPO is a cationic, dimeric, protein with a mass of
146 kDa, consisting of two 73 kDa monomers linked via a cystine
bridge at Cys153. Each monomer, which is identical and function-
ally independent, consists of two components: a 58.5 kDa, 467
amino acid, heavy chain and 14.5 kDa, 106 amino acid, light
chain.(13) The former is glycosylated and contains the modified iron
protoporphyrin IX active site. The heme group sits at the bottom of
a deep crevice,(14) which hinders access of most materials: only
H2O2 and small anions have ready access to the iron atom.(15) Other
materials that are oxidized by the enzyme (see below) bind in a
hydrophobic pocket at the entrance to the distal heme cavity. The
structures of human peroxidases have been recently reviewed
(cf. Protein Data Base accession number 1cxp for MPO).(16)
Although MPO is the most widely studied heme-peroxidase,
related species also play a critical role in metabolism, and some
major human pathologies. EPO is the major granule protein of
eosinophils, which are specialized human phagocytic cells that
eliminate parasites and related organisms.(17) Unlike neutrophils,
that phagocytose target organisms and subsequently release
MPO into phagolysosomal compartments, eosinophils exocytose
their granule contents on to the surface to which they are attached,
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as a result of the much larger size of most parasites. EPO shares
a 70% amino acid homology with MPO and is also a cationic
protein with a modified iron protoporphyrin IX heme active
site.(18) It is synthesized as a ~80 kDa single-chain precursor and
subsequently processed in to a mature protein (69.8 kDa)
consisting of a heavy (57.9 kDa) chain and light chains (11.9 kDa);
these are analogous of MPO.(16) Other related heme proteins
include salivary peroxidase and lactoperoxidase (LPO); these are
present in multiple human exocrine secretions including tears,
milk, saliva and vaginal fluid. In each case their role appears to
be as a defence against invading microorganisms.(19)
The genes for human MPO, EPO and LPO are adjacent to each
other on chromosome 17 and have similar intron-exon structures,
consistent with these arising via amplification from a common
ancestor.(20) The cationic (pI ca. 10) nature of MPO and EPO
(but not LPO) results in avid binding to negatively-charged
structures including bacterial(21–23) and endothelial cell surfaces,(24)
cytokeratin 1,(25) extracellular matrix components (especially
polyanionic glycosaminoglycan chains(26–29)), albumin,(30) cerulo-
plasmin,(31)  α1-antitrypsin,(32) and apolipoproteins A-I and B-
100.(33,34)
Reactive Intermediates Generated by Heme Peroxidases
H2O2 reacts with the native, Fe3+ form of MPO to generate the
two-electron oxidised species Compound I (an oxy-ferryl species,
Fe4+ = O, with a porphyrin π-cation radical) and water. Compound
I may be converted back to the ferric enzyme via two-electron
reduction by (pseudo) halides (“the halogenation cycle”, Fig. 1),
or via two sequential one-electron reduction reactions involving a
second intermediate (Compound II, which retains the oxy-ferryl
Fe4+ = O center; “the peroxidase cycle”, Fig. 1). An additional
intermediate, Compound III, can be generated via reaction of the
Fe3+ form with O2￿−, or via one-electron reduction to the ferrous
form and subsequent reaction with O2.
Due to the high reduction potentials of the Compound I/native
enzyme (1.16 V), Compound I/Compound II (1.35 V) and
Compound II/native enzyme (0.97) couples, MPO can oxidize
multiple substrates via its halogenation and peroxidase cycles. The
unusually high potential for MPO arises from heme distortion
and a reduction in electron density induced by a covalent vinyl
sulfonium heme linkage.(35) These redox potentials, and hence the
rate of substrate oxidation, are pH-dependent.(36) Compound III is
unreactive towards most substrates, and is usually a catalytic
‘dead-end’; this species will however slowly oxidize ascorbate(37)
and paracetamol (acetaminophen)(38) to radicals, and is implicated
in O2￿−-dependent catalytic activities of MPO.(39)
The halogenation cycle. The ability of MPO to oxidize Cl−
is unique amongst peroxidases; Br− and SCN− are also oxidized
at high rates. Each of these substrates donates two electrons to
Compound I to regenerate the ferric enzyme, with concomitant
formation of the corresponding (pseudo) hypohalous acids (HOX,
X = Cl, Br, SCN). The second order rate constants reflect the ease
of oxidation of each substrate (SCN− > Br− > Cl−). However, the rate
constants do not directly mirror the redox potentials as differences
in topology of the active site, and binding sites exert a strong
effect on substrate specificity.(16) Thus the rates of Br− and SCN−
oxidation by EPO are ~10-fold faster than for MPO,(40) even
though the MPO reduction potential is higher (1.10 vs 1.16 V).
At neutral pH and physiological concentrations of halide/pseudo-
halide ions, MPO primarily generates HOCl and HOSCN(41) with
the specificity constants for Cl−, Br− and SCN− being 1:60:730
respectively.(41) The yield of each hypohalous acid is donor
dependent, as smoking and diet can markedly elevate SCN− levels
and hence the extent of HOSCN formation from SCN−. Yields
of 5–10% and 40%, based on H2O2 consumed, have been reported
for HOBr and HOSCN formation by MPO, using mean physio-
logical ion concentrations; HOCl accounts for most of the
remainder.(41,42) In contrast, EPO primarily generates HOBr and
HOSCN, and no HOCl;(43) LPO primarily generates HOSCN.(44)
The yields of these materials is also modulated by secondary reac-
tions; HOCl and HOBr can oxidize SCN−, and HOCl can oxidize
Br−,(45,46) possibly via transhalogen species (e.g., BrCl), to the
corresponding (pseudo) hypohalous acids.
The pKa values for of HOCl, HOBr and HOSCN are 7.59,
8.7 and 4.85–5.3, respectively.(47–49) Thus at physiological pHs,
approximately equal concentration of HOCl and −OCl will be
present, HOBr predominates over −OBr, and −OSCN predominates
over HOSCN The physiological mixtures of these species are
referred to as HOCl, HOBr and HOSCN respectively, from
hereon. The rates of formation of these species by Compound I
are significantly greater at acidic pH,(40) with this believed to be
Fig. 1. The enzymatic cycles of myeloperoxidase. Initial oxidation of the resting iron (III) form of the enzyme by hydrogen peroxide gives rise to
Compound I, which is formally an iron (V) species. This intermediate can then undergo either two electron reduction with halide or pseudohalide
ions to form hypohalous acids (the halogenation cycle) or undergo two successive one electron reductions, via Compound II, with consequent
radical formation (the peroxidase cycle). The iron (III) form of the enzyme can alos undergo one electron reduction with superoxide radicals to give
Compound III. This latter reaction accounts for the SOD mimetic activity of myeloperoxidase.doi: 10.3164/jcbn.11 006FR
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due to protonation of the distal histidine.(16,50)
Whilst previous studies have disputed the formation of “free”
HOCl by MPO/H2O2/Cl−,(36,51) halogenation of large biological
targets, which cannot enter the enzyme active site, occurs both
rapidly and in near stoichiometric amounts (≥75% for heparan
sulfate based on H2O2 supplied(27,52)), consistent with the formation
of diffusible oxidants.
The peroxidase cycle. In the peroxidase cycle, radicals are
generated from substrates (both organic and inorganic) via one-
electron oxidation by Compounds I and II. O2￿− and NO￿ are also
oxidized. The catalytic activity of MPO is therefore partitioned
between halogenation and peroxidation via competition between
peroxidase substrates and (pseudo) halides for Compound I; this
partitioning is relevant to inhibition of enzymatic activity (see
below).
Physiologically- and pathologically-relevant peroxidase sub-
strates for MPO, EPO and LPO include endogenous species (e.g.,
the amino acids tyrosine and tryptophan, thiols, ascorbate, steroid
hormones and urate) as well as xenobiotics and drugs. MPO
oxidizes a wider range of substrates than EPO and LPO due to its
higher reduction potential for the Compound I/Compound II
couple (1.35 vs 1.14 V for LPO(53,54)). Substrates that react readily
with Compound I, but not Compound II, i.e. species with reduc-
tion potentials between 1.35 and 0.97 V, are often termed ‘poor’
peroxidase substrates. In the absence of additional species that
can recycle Compound II, metabolism of such substrates results in
Compound II accumulation and arrest of the catalytic cycle (see
Inhibition section below). Kinetic factors can also affect recycling
of Compound II and even with peroxidase substrates such as Tyr,
the rate constant for reaction with MPO Compound II is ~10 times
slower than for Compound I.(55)
The metabolism of Tyr by MPO and LPO is relatively insensi-
tive to pH.(55,56) With MPO, rate constants for reaction of Tyr
with Compound I are maximal at basic pH values, but vary
less than two-fold across physiologically-relevant pHs.(55) The
predominance of the chlorinating activity of MPO at acidic pH,
over its peroxidative metabolism, can be accounted for primarily
by the greater pH-dependence of Cl− oxidation.
Reactions of Hypohalous Acids
Hypochlorous acid. HOCl reacts rapidly with sulfur and
nitrogen atoms (for rate constants see (57–59)), including those
present in thiols, thioethers, amines, and amides. Thus, Cys
residues in proteins and glutathione (GSH) are key targets.(57,60–63)
Cys oxidation appears to yield a sulfenyl chloride (RS-Cl), which
undergoes rapid reaction with excess thiol, to give the disulfide,(60)
or with water to yield sulfenic (RSOH), sulfinic (RSO2H), and
sulfonic (cysteic acid, RSO3H) acids [reviewed in (64)]. Disulfides
(e.g., cystine) can be further oxidized to sulfonic acids via S-
chlorinated and S-oxygenated intermediates [reviewed in (64)].
HOCl can also induce the formation of sulfenamide (RSNR'),
sulfinamide [RS(O)NR'], and sulfonamide [RS(O)2NR'] cross-
links in peptides (e.g., GSH) and proteins,(65–67) via nucleophilic
attack of Lys or Arg side chains on RS-Cl, sulfenic or sulfinic acid
intermediates. Glutathione sulfonamide (GSSG), formed from
oxidation of GSH,(68) has been postulated as a potential marker for
MPO-mediated damage in biological systems, as it is generated
primarily by HOCl, and to a much lesser extent by other species
such as HOBr and ONOO−/ONOOH.(66,69)
The high susceptibility of Cys residues to oxidation has impor-
tant biological implications as this can disrupt the cellular redox
balance of cells by conversion of GSH to GSSG, and inactivate
multiple cellular enzymes that contain active site Cys residues.
Thus, creatine kinase and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) are rapidly inactivated by low levels of HOCl,
with this correlating with thiol depletion.(70) Conversely, HOCl can
activate the (inactive) pro- forms of matrix metalloproteinases
(MMP) (e.g., MMP-7) via conversion of a key Cys residue in the
“cysteine switch” domain of pro-MMP-7 to a sulfinic acid.(71)
Thioethers such as Met side chains are also favored targets, with
this resulting in sulfoxide formation(72) (and sulfones with very
high HOCl excesses(73)). These compounds are not useful as
markers for HOCl damage, as they are also produced by other
oxidants and can be repaired, intracellularly, by methionine
sulfoxide reductases.(74) Met oxidation can lead to alterations in
protein function by, for example, inactivating enzymes (e.g.,
lysozyme(72)), protease inhibitors (such as α1-antitrypsin),(72,75)
proteinases,(76) growth factors (e.g., GroEl(77)) and modulating
signaling pathways (e.g., oxidation of IkB with resulting inhibi-
tion of NF-kB activity(78)).
Amines, and to a lesser extent amides, are readily chlorinated
by HOCl to give chloramines (RR'NCl) and chloramides
(RC(O)N(R')Cl).(57,79,80) Dichlorination also occurs at high HOCl
excesses. Chloramines are formed on multiple biological targets
including the nitrogen atoms on: the α-amino and side-chains
of His, Lys and Arg of free amino acids and proteins; taurine;
free nucleobases, nucleosides, nucleotides and DNA/RNA;
amino sugars and glycosaminoglycans (e.g., hyaluronan, heparan
sulfates, heparin); and on the amine-containing head groups of
phospholipids (e.g., phosphatidylethanolamine, phosphatidyl-
serine).(58,59,64,81–85)
In addition to reaction with nucleophiles, HOCl undergoes
addition to aromatic rings and double bonds, including some
amino acids (Tyr and Trp), nucleobases, and fatty acid side chains
[reviewed in (64,82)]. Addition to the phenolic ring of Tyr yields 3-
chlorotyrosine (3-chloroTyr), which is widely used as a specific
marker of HOCl generation.(86,87) Secondary halogenation to give
3,5-dichlorotyrosine can also occur. Oxidation of Trp residues is
relatively rapid with this resulting in the formation of multiple
products [reviewed in Ref. 10, 64], including cyclized species
when the Trp residue is present in specific peptide sequences.(88)
Reaction of HOCl with nucleobases generates stable halogenated
products, in addition to unstable chloramines, with these including
5-chlorocytosine, 5-chloro (2'-deoxy) cytidine, 5-chlorouracil,
8-chloroadenine, 8-chloro (2'-deoxy) adenosine, and 8-chloro
(2'-deoxy) guanosine.(89–99) Some of these products have been
utilized as markers of HOCl generation.(92–100) Hydroxylated and
ring-opened species are also formed.(94,96)
HOCl reacts with the double bonds of unsaturated lipids
and cholesterol to give chlorohydrins (RCH(Cl)-CH(OH)R');
these can subsequently yield epoxides.(36,101–107) Reaction with
plasmalogen lipids, which contain a vinyl ether rather than an
ester linkage, is particularly rapid(108) with this resulting in facile
cleavage of the ether linkage to give an α-halogenated aldehyde
and a lysophospholipid.(109,110) Elevated levels of the former have
been detected in human atherosclerotic lesions.(111)
Hypobromous acid. HOBr is generally reactive and less
discriminating than HOCl (for kinetic data see (58,112,113)), though
many of the reactions are analogous to those of HOCl. It also
targets thiol, thioether, disulfide and amine functions, with the
last of these generating bromamines and bromamides. A major
difference to HOCl is in the kinetics of reaction with aromatic
rings and double bonds, with these being more rapid and important
with HOBr.(58) Thus bromination of Tyr residues (to give 3-
bromoTyr) is ~10,000-fold faster than chlorination by HOCl.(112)
This has important ramifications for the use of 3-bromoTyr and 3-
chloroTyr as markers of damage.(112) Similarly bromohydrin for-
mation is more rapid than chlorohydrin generation by HOCl, and
bromohydrins are more readily detected in biological systems.(114)
Hypothiocyanous acid. HOSCN has been postulated to be a
significant product of MPO-mediated reactions, particularly in
smokers.(115) Elevated levels of SCN− are present in such people as
a result of hydrogen cyanide formation (from cigarette combus-
tion) and subsequent metabolism. Non-smokers typically have
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have levels ≤250 μM.(116,117) This is believed to result in increased
formation of HOSCN over other MPO-derived oxidants (see
above and (118)). Furthermore, reaction of HOCl and HOBr with
SCN− can enhance HOSCN formation.
Unlike HOCl and HOBr, which are relatively promiscuous
oxidants, HOSCN is less reactive and highly selective. Thiols
are the major site of reaction,(49,119) though Trp residues are also
oxidised when Cys residues are absent or depleted.(120) This
observation is consistent with rapid reversible Cys oxidation,
and low levels of irreversible incorporation of radiolabelled
SCN− into proteins.(119–121) Thiol oxidation occurs via short-lived
RS-SCN species which rapidly react with other thiols to give
disulfides (and regenerate SCN−), or water to give a sulfenic acid
(RS-OH). The cellular effects of this oxidant are therefore, not
surprisingly, linked to damage to enzymes containing critical
Cys residues, including GAPDH(63) and protein tyrosine phos-
phatases;(122) inhibition of the latter enzymes results in increased
levels of cellular protein tyrosine phosphorylation (i.e. hyper-
phosphorylation) and altered mitogen-activated protein kinase
(MAPK) signalling. These alterations are believed to underlie the
enhanced apoptosis observed with this oxidant in some cells.(63,122)
There is little data available as to other direct reactions of
HOSCN with biological targets, though it has been reported that a
MPO/H2O2/SCN− system induces low-density lipoprotein (LDL)
modification, with resulting formation of conjugated dienes and
lipid hydroperoxides.(123) The detection of these products implies
the occurrence of radical reactions, so this may arise from the
peroxidation cycle of MPO rather than via HOSCN, though there
is also evidence for the formation of radicals from MPO-catalysed
oxidation of SCN−.(115)
Radicals. A number of different types of radical can be
generated by the peroxidase cycle of MPO i.e. as a result of one-
electron oxidation by Compounds I and II. As the redox potential
of Compound I is greater than that of Compound II, the former
can oxidise a wider range of materials. Some substrates can be
oxidised by Compound I, and not (or poorly) by Compound II
resulting in “trapping”, at least in vitro, of MPO at this point in
its enzymatic cycle. Whether such “trapping” occurs in vivo is
unclear at present, as multiple reductants (e.g., ascorbate, O2￿−)
that can convert Compound II back to the Fe3+ (native) form.
Regardless of this, a greater availability of peroxidase substrates
relative to halide ions is likely to diminish the yield of hypohalous
acids (HOCl, HOBr and HOSCN) and result in higher radical
yields. Whether this changes the overall extent of biological
damage remains an open question, with this likely to depend, to
a major extent, on the chemistry of the radicals formed (i.e.
whether they are highly reactive and induce further damage, or are
unreactive).
In some cases, termination reactions in the form of radical-
radical dimerisation, appears to be a major fate. Thus dimers and
higher polymers have been detected from phenols (e.g., dityrosine
from Tyr oxidation) with the occurrence of these reactions
minimizing further damage. Some radicals can also reduce native
MPO to Fe2+ MPO, which generates Compound III upon reaction
with O2. This occurs, for example, during MPO-mediated metabo-
lism of hydroquinone,(124,125) amsacrine,(126) hydrazines(127) and
hydrazides.(128) Other fates of MPO-generated radicals include
reaction with the parent proteins to generate protein-derived
radicals(129) and covalent addition to heme.(130,131) Radicals may
also diffuse away from the MPO and damage other biomolecules
including lipids(132,133) and proteins.(134) Radicals formed on oxida-
tion of (amino) phenols can undergo further one-electron oxida-
tion or disproportionation to generate electrophilic quinones/
quinimines that form covalent adducts with thiols (e.g., GSH) and
other biomolecules.(135,136) A number of drugs and xenobiotics
induce adverse biological effects, including agranulocytosis,
hepatotoxicity and cancer, which have been associated with their
metabolism by heme peroxidases.(136,137)
Reactions of Secondary Oxidation Products
The damaging actions of MPO persist for considerable periods
after the cessation of initial oxidant (e.g., HOCl) production.(79)
Much of the secondary damage is believed to arise from the reac-
tion of long-lived chloramines/chloramides and/or bromamines/
bromamides, formed via the reaction of HOCl/HOBr with amines
and amides (see above). The longer lifetimes of these species
allow diffusion away from the site of formation (e.g., through
cellular membranes) and the initiation of oxidative damage at
remote locations; thus extracellularly generated species may
exert intracellular effects, with the extent of cell penetration
being dependent on the structure of the halogenated species.(138–141)
Reactive aldehydes and radicals may also play a significant role
in inducing secondary damage (see above and below).
Chloramines and bromamines. Chloramines (RNHCl) and
bromamines (RNHBr), and the corresponding amide species
[RC(O)NClR'; RC(O)NBrR'] retain the oxidizing equivalents of
the parent HOCl/HOBr and can induce further reactions.(81,142,143)
Some of these processes regenerate the parent amine (which may
result in an underestimate of the extent of damage) as a result of
halogen transfer (e.g., Ref. 144, 145) or radical reactions (e.g.,
Ref. 146, 147), whereas others result in conversion of the amine
group (e.g., via hydrolysis, probably via an imine) to an aldehyde
and ammonia.(64,148–150) Aldehyde formation from bromamines
occurs more readily than from chloramines.(72,151,152) The resulting
carbonyls can react with protein or lipid amine groups to generate
Schiff base imines, which can ultimately yield advanced glycation
end  products (AGEs); the latter have been linked to vascular
disease.(153)
Halogenated amines and amides can decompose to give nitrogen-
centred radicals and subsequently carbon-centred radicals by
rearrangement reactions; both may initiate further damage.
Radical formation is promoted by low-valent redox-active metal
ions (Fe2+, Cu+) and O2￿−.(84,146,147,154,155) Halamines oxidize thiols
and thioethers (e.g., Cys and Met, respectively) though at slower
rates than HOCl and HOBr.(58,140,156) The lower reactivity of these
species results in more selective damage, and a more limited
range of products. Low pKa Cys residues are particularly susceptible
to oxidation, with this resulting in selective inactivation of some
enzymes.(141) Thiols are primarily converted to disulfides and
sulfenic/sulfonic acids (and not sulfonamides as observed with
GSH(66)). These processes can result in the induction of apoptosis
and necrosis.(141,142,157)
Activation of phagocytes has been reported to result in ~15%
conversion of the HOCl formed to chloramines,(79) whilst reaction
of HOCl or an MPO system with Escherichia coli results in up
to 50% of the HOCl being recovered as bacteria-derived
chloramines;(158) some of these materials have lifetimes of many
hours in buffer or complete media. Experiments with PMA-
activated neutrophils indicate that these chloramines are formed
on both low- and high-molecular mass materials (as determined
by mass fractionation).(158) The former appears to be primarily
taurine chloramine (which is consistent with the high concentra-
tion of this material in neutrophils), but this result may be distorted
by the discovery of rapid chlorine transfer between amine
groups,(139,144,145) and the greater stability of this chloramine over
other species. Many of the chloramines have been reported to be
hydrophilic,(158) but this conclusion may also be perturbed by the
more rapid cellular penetration of hydrophobic species, and hence
greater rate of loss of these materials via subsequent intracellular
reactions, compared to those that remained external to the cells.
Hydroperoxides. Recent studies have shown that O2￿− can
react with some of the radicals generated by the peroxidase
activity of MPO. Thus phenols can be oxidised to organic hydro-
peroxides via phenoxyl radicals that subsequently undergo radical-
radical termination reactions with O2￿−.(159,160) Such reactions occur
with both the free amino acid tyrosine (and various derivatives)doi: 10.3164/jcbn.11 006FR
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and Tyr residues present on peptides and proteins.(159–163) Some of
the factors that control the hydroperoxide yields relative to other
products (e.g., dimeric species such as di-tyrosine) have been
elucidated.(160) Similar O2￿−-dependent reactions appear to occur
with other (long-lived) radicals generated by MPO, including
those formed on urate, indoles and other related species (e.g.,
melatonin and serotonin(164,165)). The hydroperoxides formed by
these reactions may undergo further reactions resulting in the
oxidation of thiols (by two-electron oxidation reactions) and or
radicals (as a result of one-electron reduction by trace transition
metal ions). Such reactions have been characterised with a
range of other amino acid-, peptide- and protein-derived hydro-
peroxides.(166–169) These reactions may contribute to the secondary
damage induced at sites of inflammation and may rationalize the
detection of hydroxylated products from MPO-catalysed reactions.
Reactive aldehydes. Chloramines and bromamines can
decompose to yield aldehydes and ammonia with this reaction
being particularly facile with species formed on the (N-terminal)
amine groups of free amino acids and peptides.(150,170) Those
formed on side-chain amines (e.g., the є-amino group of Lys side
chains) decompose via this route to only a minor extent,(171) though
this site, and others including phospholipid head groups, can be
modified via further reactions of carbonyls formed at different
sites, via Schiff-base formation.(149,172) Some of these materials,
such as p-hydroxyphenylacetaldehye derived from the oxidation
of free Tyr residues, have been detected at elevated levels in
diseased tissues, such as atherosclerotic lesions.(172) Oxidation of
other free amino acids, such as Ser and Thr, can generate highly
reactive aldehydes, such as glycoaldehyde and 2-hydroxypropanol
(and the highly reactive α,  β-unsaturated material acrolein by
dehydration of 2-hydroxypropanol), via chloramines.(171) These
materials react rapidly with amine (e.g., Lys) and guanidine
groups (e.g., Arg residues) to products similar to the AGEs
detected in people with diabetes. Many of these materials are
potent protein cross-linking agents due to their bifunctional
nature. These compounds also form adducts with phospholipids
and DNA bases.(173) Although reactive aldehyde formation occurs
in both simple, and cellular, systems the quantitative significance
of such reactions with free amino acids (present in plasma at ≤ low
millimolar levels(174)) may be limited due to the much higher
concentrations of proteins in vivo which have similar reactive
sites.(118,168)
Cyanate. Cyanate (OCN−) is a downstream product of SCN−
oxidation by MPO, with this arising predominantly from
HOSCN.(175) Cyanate reacts with amines under physiological
conditions, with this resulting in carbamylation of N-terminal
amine groups and the Lys side chain; the latter results in
homocitrulline formation.(117) Plasma protein-bound homocit-
rulline concentrations have been reported to be an independent
predictor of cardiovascular disease (CVD), future myocardial
infarction, stroke, and death, suggesting a potential role for
HOSCN and SCN−-derived products in atherosclerosis.(117)
Modulation of Myeloperoxidase Catalytic Activity by
Other Oxidants
Both endogenous and exogenous compounds can modify the
activity of MPO, and thereby modulate the nature and extent of
oxidant formation and biological damage induced by this enzyme.
Hydrogen peroxide. Although H2O2 initiates the catalytic
cycles (halogenation and peroxidase) of MPO, it can also inhibit
MPO by acting as a competitive substrate for Compound I, by
reacting with Compound II to generate (catalytically-inactive)
Compound III, and by irreversibly inactivating the enzyme.(11,16) In
the absence of other substrates (an unlikely scenario in vivo) MPO
displays significant catalase activity, due to direct two-electron
reduction of Compound I by H2O2 to the native enzyme and to a
slower, competing process initiated via one-electron reduction of
Compound I by H2O2 to Compound II;(176) the latter process has
been proposed to occur via formation of the ferrous enzyme.(177)
Superoxide radical anion. O2￿− undergoes rapid one-electron
transfer reactions with Compounds I, II and III of MPO.(39) O2￿−
rapidly converts ferric MPO to Compound III [formally an Fe(II)
species with a bound oxygen molecule] which can be sub-
sequently recycled to the ferric form. MPO can therefore act as a
superoxide dismutase, with these reactions modulating halogena-
tion and peroxidase activity.(39) Computational modelling of reac-
tions within the neutrophil phagosome, where MPO concentra-
tions are high (ca. 1 mM), indicates that most of the O2￿− produced
by the NADPH complex is consumed via the superoxide dis-
mutase activity of MPO, and that efficient recycling of Compound
III by O2￿− ensures that phagosomal HOCl production is not
constrained.(178) Under other situations however (e.g., when the
MPO concentrations and fluxes of H2O2 are low and turnover of
the ferric enzyme is rate limiting), Compound III formation can
inhibit HOCl production (reviewed in Ref. 16, 39).
At high H2O2 fluxes, where reaction of Compound I with H2O2
results in Compound II accumulation, O2￿− can maintain MPO-
mediated chlorination by recycling Compound II to the ferric
enzyme.(16,39,179) This activity is also important in maintaining
MPO activity during the oxidation of poor peroxidase substrates
(see also below).(39,180,181)
Interaction of MPO with O2￿− can promote catalytic activities
that appear to be independent of the halogenation and peroxidase
cycles. MPO has been shown to hydroxylate aromatic substrates,
such as phenols(182) and salicylate,(183) and oxidize melatonin via
O2￿−-dependent processes.(164) These reactions may occur via
reaction of ferric MPO with O2￿− to form Compound III, and
involve a reactive intermediate such as singlet oxygen (1O2).(164)
Aromatic hydroxylation is also observed during the metabolism
of the hydrazide derivative isoniazid by MPO where Compound
III is generated.(127) As discussed above, it is now established that
O2￿− can react with some of the radicals generated by MPO, to
yield hydroperoxides, and subsequent decomposition of these
species may account for the formation of some of these hydroxy-
lated products.
Nitric oxide. NO￿ reacts rapidly with Compounds I and II of
MPO via one-electron transfer.(184) The initial product of these
reactions, the nitrosonium ion (NO+), is a short-lived species that
reacts with water to yield NO2− which may ultimately result in the
formation of nitrosylated products.(185) The interaction of NO￿ with
MPO may therefore alter the distribution of redox intermediates
during steady state catalysis, and the balance between halogena-
tion and peroxidase cycles.(186–188) Although the reactions of NO￿
with MPO Compounds I and II are facile, MPO-dependent
consumption of NO￿ in human plasma at physiologically-relevant
fluxes (steady state << 1 μM) is likely to predominantly occur via
reaction with radicals generated by the peroxidase cycle (e.g.,
tyrosyl and ascorbate radicals).(189)
Nitrite. NO2− is a major decomposition product of NO￿ and is
generated by autoxidation (via the formation of N2O3) or from
metabolism by heme proteins such as hemoglobin(190) or peroxi-
dases (see above). NO2− reacts with Compound I and Compound II
of MPO(191,192) to generate NO2￿. With MPO a small but significant
fraction of NO2− is oxidized to a species that can induce hydroxyl-
ation as well as nitration, a property shared by peroxynitrite
(ONOO−/ONOOH). In contrast to free peroxynitrite, MPO-H2O2-
NO2− induces aromatic hydroxylation only at acidic pH, and CO2
does not enhance aromatic nitration, consistent with an enzyme-
bound intermediate.(193) Analogous experiments with LPO indicate
that this intermediate may be a complex of ONOO− with MPO.(194)
Peroxynitrite. Whilst NO￿ and O2￿− have important, indepen-
dent interactions with MPO the radical-radical termination
product of these species, ONOOH also reacts. Thus ferric MPO
can promote aromatic nitration by peroxynitrite.(195) Ferric MPO
appears to be directly converted to Compound II, consistent with J. Clin. Biochem. Nutr. | January 2011 | vol. 48 | no. 1 | 13
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the generation of NO2￿.(196,197) Reaction with ferric MPO is faster at
acidic pHs, with the pH dependency consistent with the pKa of
ONOOH/ONOO−, suggesting that ONOOH is the reactant,(196) and
that Compound II formation occurs via dissociation of an inter-
mediate oxygen-coordinated complex of ONOO− (see also pre-
ceding section).(197) Peroxynitrite also rapidly converts Compound
I and Compound III, to Compound II. Compound II does not
appear to oxidize peroxynitrite, despite this process being thermo-
dynamically favorable.(197)
Inhibition of Myeloperoxidase Activity
In the light of the data supporting a role for MPO in a range of
human diseases (reviewed in (10,12)), there is considerable interest
in the development of MPO inhibitors. A number of different
strategies to limit oxidant formation and damage have been inves-
tigated; these are summarised below.
Limiting the availability of substrates for oxidant
production. MPO-mediated oxidant generation can obviously
be limited by decreasing the availability of H2O2. This can be
achieved by inhibiting the membrane-bound NOX of phagocytes,
and related NOXs present in other cells (e.g., endothelial and
smooth muscle cells(198,199)). A number of such compounds have
been identified,(200,201) with the most extensively studied being
diphenylene iodonium chloride (DPI).(202,203) This compound also
inhibits other sources of O2￿− formation (and hence H2O2 levels)
including mitochondrial activities.(204) Despite the undoubted
utility of these compounds in isolated systems, the plethora of
sources of O2￿− and H2O2 in vivo, may limit the usefulness of this
strategy in some cases. Furthermore, low levels of H2O2 appear to
be required for cell signalling, and hence limiting O2￿− formation
may not be always beneficial.
NO￿ can suppress NOX activity in endothelial cells via S-
nitrosylation of the p47phox subunit(205) and thus may limit MPO-
mediated damage by decreasing vascular H2O2 concentrations, in
addition to its direct effects on MPO activity (see above). Whether
sufficient NO￿ is present in vivo to have a major modulatory effect
on MPO activity, in addition to its multitude of other effects,
remains an open question. Oxyhemoglobin oxidises NO￿ and NO2−
to the inactive product NO3− and thus may be an important
intravascular modulator of peroxidase-dependent and -independent
nitration.(206)
Whilst modulation of Cl− levels is clearly not readily achievable
in most situations, the levels of Br−, I− and SCN− can be modulated
by dietary or other means (e.g., cessation of smoking for SCN−).
Whilst lower levels of these ions can modulate the nature of the
oxidants formed, the overall yield may not to be markedly
affected, as HOCl formation may then predominate.
Heme poisons. Small anions, including azide and cyanide,
can bind competitively to the heme centre of MPO in place of its
typical halogenation substrates, thereby inhibiting hypohalous
acids formation. The use of these agents is, however, limited
by their multitude of interactions with other heme centres and
subsequent toxicity.
MPO binding agents. Caeruloplasmin, a copper-containing
plasma protein, binds MPO avidly(31) and inhibits its peroxidase
and halogenation activities.(31,207) This protein may therefore limit
the activity of MPO in plasma. Anti-MPO antibodies can reverse
this inhibition.(208) The nature of some of these caeruloplasmin-
MPO complexes has been investigated.(209) Polyanionic glycos-
aminoglycans, such as the anticoagulant heparin, bind (cationic)
MPO electrostatically,(28) and can liberate MPO sequestered in the
artery wall.(210) This interaction with MPO may exacerbate damage
to heparin, or other glycosaminoglycans to which it is bound,(84,155)
but divert oxidation from other critical sites. Modulation of MPO
activity in this fashion could be an important, additional function
of heparin in vivo. However in situations where both protein and
glycosaminoglycans are present (e.g., on proteoglycans, such as
the basement membrane species perlecan), damage appears to be
primarily localised to the protein, with this resulting in changes to
proteoglycan function.(27)
Phenols and other poor peroxidase substrates. Sub-
strates that react readily with Compound I, thereby competitively
inhibiting halide/pseudohalide ion oxidation, are a potentially
attractive mechanism of inhibiting hypohalous acid formation. If
such materials are poorly oxidised by Compound II, then these
materials may “trap” the enzyme and prevent completion of the
catalytic cycle (though see the caveats discussed above, regarding
in vivo significance). The potential of this approach is however,
limited by the high drug concentrations required to compete with
halide oxidation. Some plasma components may exhibit this be-
haviour, with both ascorbate and urate oxidised by MPO;(211,212) the
quantitative significance of these reactions in vivo remains to be
fully established.
A number of non-steroidal anti-inflammatory drugs have been
shown to inhibit the formation of HOCl (and other hypohalous
acids) by MPO by acting as poor peroxidase substrates for the
enzyme.(211,213) The most effective agents are likely to be those
with redox potentials between 1.35 and 1.1 V, which results in
significant rates of oxidation by Compound I, but not Compound
II.(211,214) As O2￿− can reduce Compound II to the ferric state, these
compounds would be expected to be most effective (i.e. have
lower IC50 values, the concentration of drug required to produce
50% inhibition) in the presence of SOD in vitro.(215) This is
unlikely to happen within the neutrophil phagosome however,
where the SOD concentration is limited.(11)
The common anti-inflammatory drug paracetamol (acetamino-
phen) reaches some of the highest plasma concentrations of any
exogenous compound. Thus standard pharmacological doses (1 g)
give peak plasma levels of up to 130 μM.(135) Such levels result in
marked inhibition of HOCl and HOBr generation by MPO-H2O2-
halide systems (IC50 77 μM for HOCl formation, 19 μM for
HOBr formation, and 92 μM for both (52)). Similar inhibition of
hypohalous acid formation was detected with activated neutro-
phils (IC50 ~ 100 μM), without perturbation of O2￿− formation.(52)
This inhibition is accompanied by paracetamol dimer formation
as a result of oxidation of the drug to the corresponding phenoxyl
radical and subsequent dimerisation;(52) these dimers may act as a
useful marker of MPO inhibition by this drug.(52) Further trials of
paracetamol in humans are under way.
Other phenols may behave in a similar manner, but whether
these compounds achieve sufficiently high plasma concentrations
to be effective in vivo is unclear. Recent studies have reported
that flavanoids may act as MPO substrates, with this resulting in
irreversible inactivation, and oxidation of the flavonoid to a
radical and subsequent dimerization. In the presence of GSH,
hydroquinone formation was detected and subsequent GSH
conjugation.(216) Despite this interaction, the yield of chlorinating
oxidants was not markedly affected, and therefore it was con-
cluded that these materials were unlikely to be pharmacologically
useful.(216) In contrast, quercitin, and some analogues and metabo-
lites, has been shown to be an effective inhibitor (IC50 ~ 1 μM for
quercitin) of neutrophil-mediated LDL modification, with this
ascribed to inhibition of MPO-mediated oxidant formation by
quercitin.(217) The effect of the flavonoids and related materials
may therefore be complex and structure dependent. As many of
these materials have low biological availability (i.e. peak plasma
concentrations being nM or low μM(218)) very low μM IC50 values
for MPO inhibition would be required for any biological effect.
As might be expected on the basis of the above data, anilines
and indoles (including the amino acid tryptophan(219–221) and
analogues(222)) are readily oxidized by MPO Compound I, and
act as poor peroxidase substrates (i.e. result in the accumulation
of Compound II, and in cases Compound III(219)). As with phenols,
these compounds show lower IC50 values in the presence of
SOD, as a result of the removal of O2￿−.(219) The efficiencies anddoi: 10.3164/jcbn.11 006FR
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mechanisms of inhibition by different tryptophan analogues has
been examined.(222) These studies indicate that structural changes,
particularly those that increase hydrophobicity, increase the effec-
tiveness of these materials.
An alternative approach has also been examined: rather than
providing a substrate that can be metabolized to a radical by MPO
(which might be damaging), stable radicals that might be metabo-
lized to non-radical products were examined.(215) Thus long-lived
nitroxide radicals, that do not give rise to overt toxicology in
extended feeding studies,(223) have been examined as MPO
inhibitors. A number of these compounds are potent inhibitors of
MPO-mediated oxidant formation, from both isolated MPO and
activated neutrophils, with IC50 values in the low μM range.(215)
Evidence has been presented for Compound II accumulation with
some nitroxides, but others appear to induce heme destruction.(215)
The IC50 values show a marked structure dependence with
positively-charged species being much more effective than
negatively-charged; this has been ascribed to an interaction
between the nitroxide and negatively-charged groups on the
enzyme. In vivo studies are required to elucidate the true thera-
peutic potential of these compounds.
A number of other drugs, including hydroquinone(124) and
amsacrine,(126) can also divert MPO from HOCl production via
an alternative mechanism by promoting Compound III formation;
again O2￿− would be expected to antagonise this inhibition, by
recycling this species to the native enzyme.
Hydrazines and hydrazides. The most “effective” (i.e.
lowest IC50 values) inhibitors of MPO are irreversible enzyme
inhibitors (‘suicide’ substrates); these include hydrazines
(RNHNH2) and hydrazides (RCONHNH2).(224–226) Despite their
low IC50 values these compounds may not however be the most
applicable in vivo. Benzoic acid hydrazides, including the most
potent MPO inhibitor identified to date, 4-aminobenzoic acid
hydrazide (ABAH),(128) are believed to act via heme destruction
arising from generation of ferrous MPO,(224) however the precise
mechanism is uncertain. Irreversible inhibition of MPO by the
hydrazide derivative isoniazid, an anti-tuberculosis drug, has also
been proposed to involve heme modification via a mechanism
initiated by Compound III formation.(227)
Conclusions
There is now considerable evidence that MPO and other heme
peroxidases are enzymes that have both beneficial and damaging
actions. These species have a clear beneficial function in terms
of killing invading pathogens, but this same enzymatic activity
can result in host tissue damage and play a role in a number of
important human pathologies. Information and an understanding
of the enzymology and mechanisms of action of these enzymes is
clearly therefore of major importance, both in terms of enhancing
their positive actions in terms of disinfection and improved
hygiene, and diminishing their deleterious effects. Recent studies
have provided valuable information on the targets and actions
of the oxidants generated by these enzymes and their mechanisms
of biological damage. Ongoing studies on the control of the
halogenation and peroxidase cycles are providing valuable data
on new therapeutic strategies to limit oxidant damage to human
tissues and it is possible that selective inhibition of these enzymes
will have major clinical benefits.
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Abbreviations
NOX NADPH oxidase
O2￿− superoxide radicals
H2O2 hydrogen peroxide
HO￿ hydroxyl radicals
MPO myeloperoxidase
NO￿ nitric oxide
ONOOH peroxynitrite
EPO eosinophil peroxidase
LPO lactoperoxidase
GSH glutathione
GSSG glutathione disulfide
MMP matrix metalloproteinases
3-chloroTyr 3-chlorotyrosine
MAPK mitogen-activated protein kinase
AGEs advanced glycation end products
CVD cardiovascular disease
1O2 singlet oxygen
NO+ nitrosonium ion
DPI diphenylene iodonium chloride
ABAH 4-aminobenzoic acid hydrazide
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